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Abstract
Background: Bedtime administration of antihypertensive drugs currently receives more at-
tention, but no clear consensus has been reached on the blood pressure (BP)-lowering effect of 
this strategy.
Methods: We systematically searched literature for clinical trials of ingestion time of anti-
hypertensive drugs evaluated by ambulatory blood pressure monitoring (ABPM) to perform 
a meta-analysis which aimed at determining the difference in diurnal, nocturnal, and 24-h 
mean of systolic BP (SBP) and diastolic BP (DBP), absolute BP reduction from baseline 
between bedtime administration group (experimental group) and morning (awaking) admin-
istration group (control group).
Results: The synthesis analysis showed that the level of BP in bedtime administration 
group was lower than the morning administration group, which reduced diurnal SBP/DBP 
by 1.67/1.13 mm Hg (p = 0.36/0.48), 24-h SBP/DBP by 2.78/0.36 mm Hg (p = 0.09/0.62), 
nocturnal SBP/DBP by 6.32/3.17 mm Hg (p = 0.03/0.007). Furthermore, there was lack of 
statistically significant differences in the diurnal mean of SBP/DBP reduction from base-
line between the two groups (p = 0.94/0.85), but bedtime administration resulted in sig-
nificant reduction from baseline in the nocturnal mean of SBP/DBP, by –4.72/–3.57 mm Hg  
(p = 0.01/0.05). Funnel plot demonstrated that there was no evidence of publication bias.
Conclusions: Administration of ≥ 1 antihypertensive drugs at bedtime or evening results in  
a greater reduction of nocturnal hypertension than dosing in the morning without loss of  
efficacy of diurnal and 24 h mean BP reduction. (Cardiol J 2016; 23, 4: 473–481)
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Introduction
Hypertension is a global public health issue. As 
the World Heart Association data shows, globally car-
diovascular (CV) disease accounts for approximately 
17 million deaths a year, nearly one third of the total CV 
disease population. Of these, complications of hyper-
tension account for 9.4 million deaths worldwide every 
year. Hypertension is responsible for at least 45% of 
deaths due to heart disease and 51% due to stroke [1].
In recent hypertension guidelines [2–7], the 
criteria for hypertension in different measurement 
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methods and the drugs recommended for treating 
hypertension with different clinical conditions are 
clear, but uncontrolled hypertension which may 
lead to serious CV events, increase dosage, and 
have lifethreatening consequences is present in 
most patients treated with only a single morning 
dose or fixed dose drug combination [8], therefore 
monitoring and management of high blood pressure 
(BP) is crucial. The mean nocturnal BP value has 
been suggested as the most sensitive predictor of 
cardio- and cerebrovascular morbidity and mor-
tality, in other words, insufficient BP fall at night 
compared to daytime level or a non-dipping pattern 
is associated with elevated risk of end-organ injury, 
particularly to heart (left ventricular hypertrophy, 
congestive heart failure and myocardial infarc-
tion), brain (stroke), and kidneys (albuminuria and 
progression to end-stage renal failure), as well as 
poor prognosis [9–11]. Decreasing nighttime BP 
and bedtime administration of antihypertensive 
drugs have already been taken into account for the 
treatment strategy aiming to improve BP manage-
ment, but no clear consensus has been reached 
on the BP-lowering effect of this strategy. Recent 
researches have documented that ingesting at 
least one antihypertensive medication at bedtime, 
compared with treatment with all medications upon 
awakening, showed a significant reduction in the 
24-h mean systolic BP (SBP)/diastolic BP (DBP) 
and the reduction was much more prominent dur-
ing nighttime, decreasing the prevalence of non-
dipping [8, 11, 12], however, the similar 24-h mean 
SBP/DBP reduction for both treatment times was 
also reported [13–15]. Therefore, we conducted 
this meta-analysis to investigate the effects of 
bedtime administration of BP-lowering agents on 
ambulatory BP monitoring (ABPM) results.
Methods
Literature search
This meta-analysis was conducted in accord-
ance with PRISMA guidelines [16]. ISI Web of 
Science, Embase, Cochrane, and Pubmed were 
searched in October 2015 using combinations of the 
following search terms: bedtime administration, 
night, evening, antihypertensive drugs, antihy-
pertensive effect. No restrictions were imposed. 
The reference lists of all retrieved articles were 
also reviewed to identify additional articles missed 
by using these search terms. All searches were 
performed independently by two investigators and 
disagreements were resolved by consensus.
Inclusion criteria
Studies were included if they met the following 
criteria: 1) Adult patients who satisfied the diagno-
sis criteria of hypertension (SBP ≥ 140 mm Hg or 
DBP ≥ 90 mm Hg), including essential hyperten-
sion and secondary hypertension; 2) Randomized 
or non-randomized experimental trials with at least 
8 weeks’ treatment duration of antihypertensive 
drugs (angiotensin-converting enzyme inhibitors, 
calcium channel blockers, beta-blockers, diuretics, 
angiotensin receptor blockers, and alpha-blockers); 
3) Intervention was defined as one or more anti-
hypertensive drugs administered at bedtime (from 
5:00 p.m. to 12:00 midnight), the control group was 
matched to the experimental group by drug and 
dose but with a morning regimen or in awaking 
time (from 6:00 a.m. to 12:00 noon); 4) The pre- and 
post-treatment SBP and DBP of each patient were 
measured by ABPM. ABPM is now the gold stand-
ard method and the most cost-effective strategy for 
diagnosing hypertension, evaluating true BP level 
[17]. It has been shown to be a better predictor of 
CV morbidity and mortality as compared to office 
BP measurements [18].
Data extraction
We extracted the following data from each 
of the studies included: the first author, year of 
publication, study country, sample size, patient 
characteristics (age, gender, hypertension type), 
interventions (grouping, types of drugs, interven-
tion duration), and study design. Any discrepancies 
were resolved by discussion. All of the obtained 
data were examined carefully for accuracy. Cor-
responding authors were contacted by email for 
additional information needed in this meta-analysis.
Statistical analysis
All included studies were grouped according 
to the intervention regimen. The data from each 
included trial were analyzed using Review Manager 
(RevMan, Version 5.1, Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 
2011). The meta-analysis was performed using the 
generic inverse variance. Statistical heterogeneity 
among studies was assessed using I2 statistic. Mild, 
moderate, and severe heterogeneity were defined 
by I2 values of 25%, 50%, and 75%, respectively. 
The random-effect model was applied throughout 
this meta-analysis, regardless of I2 value, in order 
to get a consistent conclusion. The funnel plot was 
used to assess the presence of publication bias. 
P £ 0.05 was considered statistically significant.
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Results
Flow of included studies
A total of 252 studies were identified by 
searching ISI Web of Science, Embase, Cochrane, 
and Pubmed. Fifty-one studies were duplicates, 183 
were irrelevant, 18 relevant full-text studies were 
assessed for eligibility, and finally 6 trials fulfilled 
the inclusion criteria (Fig. 1).
Study characteristics
A total of 1,566 hypertensive individuals from 
6 clinical trials were included in this meta-analy-
sis. The 6 studies were randomized controlled 
trials (RCTs), one had a crossover design and 
the others were of a parallel design. Three stud-
ies were conducted in Spain but on independent 
groups of participants, 1 in Japan, 1 in Israel, 
1 in Denmark. The numbers of participants were 
ranged from 41 to 661. The treatment duration of 
antihypertensive drugs ranged from 8 weeks to 
5.4 years. The population of hypertension (pri-
mary or secondary, with or without type 2 diabetes 
mellitus) and the antihypertensive drugs among 
the trials were different, representing substantial 
heterogeneity. Detailed information of the 6 trials 
was shown in Table 1.
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Figure 1. Flowchart for eligible studies.
www.cardiologyjournal.org 475
Yuanyuan Sun et al., The BP-lowering effects of bedtime dosing antihypertension drugs
Diurnal mean of SBP/DBP
All 6 studies were included in the analysis, 
which concerned 1,566 cases of hypertension; 779 
cases were in the bedtime administration group 
(experimental group) and 787 cases in the morning 
(awaking) administration group (control group). The 
synthesis analysis showed that the diurnal mean of 
SBP in bedtime administration group was lower than 
the morning administration group, which reduced 
diurnal SBP by 1.67 mm Hg (95% CI –1.89–5.23, 
p = 0.36) (Fig. 2A), diurnal DBP by 1.13 mm Hg 
(95% CI –2.03–4.28, p = 0.48) (Fig. 2D).
Nocturnal mean of SBP/DBP
All 6 studies were included in the analysis. The 
synthesis analysis showed that the nocturnal mean 
of SBP in bedtime administration group was lower 
than the morning administration group, which re-
duced nocturnal SBP by 6.32 mm Hg (95% CI 0.62– 
–12.01, p = 0.03) (Fig. 2B), nocturnal DBP by 
3.17 mm Hg (95% CI 0.85–5.49, p = 0.007) (Fig. 2E).
24-h mean of SBP/DBP
In a research by Kario et al. [14], no 24 h 
mean of SBP/DBP was found, therefore 5 studies 
were included in the analysis, which concerned 
1,116 cases of hypertension, 558 cases were in the 
experimental group and 558 cases in the control 
group. The synthesis analysis showed that the 24-h 
mean SBP in experimental group was lower than in 
the control group, which reduced 24-h SBP by 2.78 
mm Hg (95% CI –0.47–6.02, p = 0.09) (Fig. 2C), 
24-h DBP by 0.36 mm Hg (95% CI –1.08–1.80, 
p = 0.62) (Fig. 2F).
Absolute BP reduction from baseline
As the BP baselines of patients included in the 
researches were different, we analyzed the abso-
lute reduction amplitude of diurnal and nocturnal 
BP. Three studies were taken into the analysis, 
which included 763 cases of hypertension, 379 
cases were in the experimental group and 384 
cases in the control group. There was a lack of 
statistically significant differences in the diurnal 
mean of SBP and DBP reduction from baseline be-
tween the two groups (p = 0.94/0.85) (Fig. 3A, B), 
but bedtime administration resulted in significant 
reduction from baseline in the nocturnal mean of 
SBP/DBP, by –4.72/–3.57 mm Hg (p = 0.01/0.05) 
(Fig. 3C, D).
Risk of bias in the included studies
Funnel plot was used to assess the publica-
tion bias in the literature. The overall assessment 
of the risk of bias is shown in Figure 4. Funnel 
plot demonstrated that there was no evidence of 
publication bias.
Discussion
The synthesis analysis showed that the lev-
el of BP in the bedtime administration group 
was lower than in the morning administration 
group, which reduced diurnal SBP by 1.67 mm Hg 
(95% CI –1.89–5.23, p = 0.36), diurnal DBP by 
1.13 mm Hg (95% CI –2.03–4.28, p = 0.48), 24-h 
SBP by 2.78 mm Hg (95% CI –0.47–6.02, p = 0.09), 
24-h DBP by 0.36 mm Hg (95% CI –1.08 –1.80, p = 
0.62). There is no statistically significant. A recent 
Cochrane review [19] found evening administra-
tion lowered 24-h SBP by 1.61 mm Hg and 24-h 
DBP by 1.23 mm Hg, which was a statistically sig-
nificant difference. In particular, the alpha-blocker 
doxazosin GITS (4 mg/day) [20] and the diuretic 
torasemide (5 mg/day) [21] evening administration 
reduced 24-h SBP by 5.10 mm Hg and 6.24 mm 
Hg, respectively and 24-h DBP by 2.70 mm Hg 
and 5.95 mm Hg, respectively. The two researches 
were excluded according to our inclusion criteria 
(intervention and duration).
Our meta-analysis showed that the nocturnal 
mean of SBP in the bedtime administration group 
was lower than in the morning administration 
group reducing nocturnal SBP by 6.32 mm Hg (95% 
CI 0.62–12.01, p = 0.03) and nocturnal DBP by 
3.17 mm Hg (95% CI 0.85–5.49, p = 0.007). Bed-
time administration resulted in significant reduc-
tion from baseline in the nocturnal mean of SBP/ 
/DBP, by –4.72/–3.57 mm Hg (p = 0.01/0.05). Her-
mida et al. [13] found that each 5-mm Hg decrease 
in mean sleep-time SBP was associated with a 14% 
reduction in the risk for CV events during follow-up 
(p < 0.001) among patients with chronic kidney 
disease and hypertension. Rossen et al. [12] found 
levels of C-reactive protein were significantly 
lower with bedtime administration among patients 
with type 2 diabetes mellitus and nocturnal hyper-
tension (p = 0.017), which may indicate an effect 
on low-grade inflammation.
With the widespread use of ABPM, nocturnal 
hypertension usually accompanied by non-dipping 
status has received increasing attention. O’Brien et 
al. [7] reported for the first time that an abnormal 
circadian BP profile with a nocturnal SBP/DBP 
decline of less than 10/5 mm Hg led to an increased 
risk of stroke in 1988. Compelling evidence is now 
available, showing that nocturnal BP is superior to 
daytime BP in predicting outcomes [7]. Subsequent 
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Figure 2. Forest plot showing diurnal mean of systolic blood pressure (SBP) (A), nocturnal mean of SBP (B), 24-h mean 
of SBP (C), diurnal mean of diastolic blood pressure (DBP) (D), nocturnal mean of DBP (E), 24-h mean of DBP (F) in 
the experimental group and control group; CI — confidence interval.
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studies in different populations and hypertensive 
patients corroborated the fact that a diminished 
nocturnal fall in BP was associated with poor CV 
outcomes and superior to daytime BP in predicting 
CV events and total mortality [12]. It was found 
that for every increase of 10 mm Hg in mean SBP 
at night, the risk of death increased by 21% [7]. 
According to the IDACO (an International Database 
on Ambulatory BP in relation to Cardiovascular 
Outcome) database, a 16-mm Hg increase in the 
nocturnal SBP was associated with stroke events 
(HR 1.08 [1.01–1.16]; p < 0.001) [10]. In 1,187 
essential hypertension patients followed up for 
3.2 years, Krzych et al. [22] found that the oc-
currence of adverse CV events was nearly three 
times higher in non-dipper patients than dipper 
hypertensive patients [22].
Multiple factors alone or in combination can 
lead to nocturnal hypertension in 1 person. The 
activity of the sympathetic nervous system de-
termines the circadian variation of BP. Nocturnal 
hypertension is more common in patients with 
diabetes mellitus, sleep disturbance, depression 
and anxiety disorder, and cerebrovascular diseases 
accompanied by elevated sympathetic nervous ac-
tivity during sleep [10, 12, 23]. Bankir et al. [24] pro-
posed a pressure natriuresis mechanism hypothesis 
that the relative increase in BP observed during the 
night is in favor of a compensatory rise in sodium 
excretion and the maintenance of sodium balance. In 
other words, the non-dipping pattern of BP at night 
is caused by an impaired capacity to excrete sodium 
due either to a reduced glomerular filtration rate or 
to a primary increase in tubular sodium reabsorp-
tion during daytime. Hence, BP rises at night to 
promote sodium excretion to maintain 24-h sodium 
balance [24]. An abnormal BP dipping has been 
reported in several clinical conditions associated 
with an impaired renal function (e.g., aging or renal 
transplantation) or an increased sodium reabsorp-
tion (e.g., primary hyperaldosteronism, ciclosporin, 
or administration of nonsteroidal anti-inflammatory 
Figure 3. Forest plot showing absolute blood pressure reduction from baseline of diurnal mean of systolic blood pres-
sure (SBP) (A)/diastolic blood pressure (DBP) (B), nocturnal mean of SBP (C)/DBP (D) in the experimental group and 
control group; CI — confidence interval.
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Figure 4. Funnel plot was drawn to assess the publication bias in the literature; A. Diurnal mean of systolic blood 
pressure (SBP); B. Nocturnal mean of SBP; C. 24-h mean of SBP; D. Diurnal mean of diastolic blood pressure (DBP); 
E. Nocturnal mean of DBP; F. 24-h mean of DBP.
drugs) [25]. Reduced melatonin secretion leading to 
disturbed BP rhythmicity-chronodisruption is also 
involved in the pathophysiology of nocturnal BP 
alterations. Non-dipping patients express a lower 
nocturnal surge of melatonin release, as reflected by 
reduced 6-sulfatoxymelatonin in urine and a lower 
ratio of the night/day concentration of melatonin 
[26]. Finally, the medications widely used in clinical 
conditions may have short half-life and duration of 
action, failing to provide a full 24 h coverage, when 
taken in the morning.
Nowadays, majority of hypertensive patients 
are treated with combination therapy, especially 
in patients with grade 2 or above essential hyper-
tension and secondary hypertension to achieve 
an adequate BP control [27]. The influence of 
combination therapy in different administration 
time on antihypertensive efficacy studies have 
demonstrated that once-daily antihypertensive 
agents have the highest adherence compared with 
twice-daily or multiple daily doses. The evidence 
suggests that an antihypertensive medication 
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adherence of 80% or more appears to improve 
BP control and decrease the risk of developing 
some of the complications of hypertension [28]. 
Antihypertensive drugs are most often given with 
morning food in the traditional manner for the sake 
of convenience [29, 30]. An optimal once-daily 
hypertension therapy would not only lower BP but 
also normalize any blunted circadian variations in 
BP. Farah et al. [8] found that switching the therapy 
to bedtime improved BP control and helped avoid 
the non-dipper pattern without increasing the dose 
or adding more drugs.
The compliance was comparable between the 
two groups. In Kario’s trial [14], 11 (5%) patients 
in the bedtime administration group and 18 (7.9%) 
in the morning administration group did not com-
plete the study. In Rossen’s trial [12], all patients 
met the criteria of compliance. No withdrawal was 
reported in the left trials.
The mechanisms for these observed treat-
ment-time differences remain unclear, but it has 
been generally agreed that the pharmacokinet-
ics (PK) — the study of what the body does to 
a drug, absorption, distribution, metabolism, and 
elimination — and pharmacodynamics (PD) — the 
study of what a drug does to the body — of the 
medications occurring in relation to the 24 h cyclic 
processes were involved in BP regulation [11, 
31]. Circadian rhythms in gastric pH and empty-
ing, gastrointestinal motility, biliary function and 
circulation, liver enzyme activity, and blood flow 
to the duodenum, kidney, and other organs, among 
other factors can lead to ingestion-time differ-
ences in the PK of conventional antihypertensive 
medications [8, 11]. In particular, the circadian 
pattern of the glomerular filtration rate, with 
a maximum during the day and a minimum at 
night, played a significant role [8, 11, 32]. Con-
sequently, antihypertensive drugs were cleared 
more slowly overnight, potentially prolonging 
their duration of action when ingested at bedtime 
as compared to taken at awakening. Taking-time 
differences in the PD of antihypertensive drugs, 
both the therapeutic and side effects, result 
from the time-dependency in their PK, as well 
as from circadian rhythms in drug-free fraction, 
rate-limiting steps of key metabolic processes, 
receptor number and conformation, and/or sec-
ond messenger and signaling pathways [11]. The 
result of Hermida et al.’s [11] spirapril study was 
consistent with the theory. The BP-lowering ef-
ficacy duration of spirapril was much longer when 
taken at bedtime (8 h after ingestion) than in the 
morning (3 h after ingestion).
At present, there is little literature on the topic 
and even much fewer RCTs. Three of the 6 articles 
included in our analysis were reported by Hermida, 
but the studies were conducted with independent 
groups of participants with different study drug, 
follow-up time and team. According to our pre-set 
inclusion criteria and the key research indicators, 
the overall quality of the studies included in our 
meta-analysis was good. The conclusion of this 
meta-analysis is reliable. The research is of great 
significance to provide a reference for the clinical 
physicians to make the optimized regimen of anti-
hypertensive drugs.
Limitations of the study
Our meta-analysis had several limitations. 
First, the duration periods of the trials included 
were not long enough except for one research 
[13], therefore we cannot assess the relationship 
between nighttime BP-lowering level and protec-
tion against end-organ injury and CV morbidity and 
mortality in hypertension patients with different 
complications. Second, as there are many kinds 
of anti-hypertension drugs with different action 
mechanisms and metabolic characteristics, we 
need a large sample of cases and long follow-up to 
assess their different effects on clinical benefit of 
lowering nocturnal hypertension. Third, includ-
ing populations of non-dipper patients (2 out of 
6 included studies) could introduce an important 
source of bias. Due to not enough literature, if the 
2 studies were excluded, the conclusion extrapo-
lation would be even worse, therefore no analysis 
was conducted this paper.
Conclusions
Despite the limitations of our meta-analysis, 
we conclude that taking the antihypertensive drugs 
at bedtime demonstrated a similar reduction in the 
level of diurnal and 24-mean BP as morning dosing, 
but a significant reduction in nocturnal BP. Switch-
ing time of taking antihypertensive medicine from 
morning to bedtime or evening can have a better 
nocturnal BP control and restore or maintain the 
normal BP pattern which may be better for prog-
nosis. Hypertension patients, especially those who 
had nocturnal hypertension or non-dipping BP 
pattern under the condition of evaluated BP level 
by 24-h-ABPM, should be suggested that they take 
their drugs at bedtime without changing the drug 
itself or the dose.
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